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a B s t r a c t
Galectin-3 is a lectin involved in fibro-
sis, inflammation and proliferation. 
increased circulating levels of galec-
tin-3 have been associated with various 
diseases, including cancer, immuno-
logical disorders, and cardiovascular 
disease. to enhance our knowledge on 
galectin-3 biology we performed the 
first genome-wide association study 
(Gwas) using the illumina Human-
cytosnP-12 array imputed with the 
Hapmap 2 ceu panel on plasma ga-
lectin-3 levels in 3,776 subjects and 
follow-up genotyping in an additional 
3,516 subjects. we identified 2 genome 
wide significant loci associated with 
plasma galectin-3 levels. one locus har-
bours the LGALS3 gene (rs2274273; 
P=2.35 × 10-188) and the other locus the 
ABO gene (rs644234; P=3.65 x 10-47). 
The variance explained by the LGALS3 
locus was 25.6% and by the ABO lo-
cus 3.8% and jointly they explained 
29.2%. rs2274273 lies in high link-
age disequilibrium with two non-syn-
onymous snPs (rs4644; r2=1.0, and 
rs4652; r2=0.91) and wet lab follow-up 
genotyping revealed that both are 
strongly associated with galectin-3 lev-
els (rs4644; P=4.97 × 10-465 and rs4652 
P=1.50 × 10-421) and were also associat-
ed with LGALS3 gene-expression. The 
origins of our associations should be 
further validated by means of function-
al experiments.








5 0 5 1
i n t r o d u c t i o n
Galectin-3 (LGALS3) is a lectin and 
member of the galectin family of car-
bohydrate binding proteins that have 
an affinity for beta-galactosides. Galec-
tin-3 plays a role in fibrosis, inflamma-
tion, and proliferation.1-3 Galectin-3 is 
secreted into the systemic circulation 
by unknown mechanisms and is in-
creasingly recognised as a potential bi-
omarker with clinical value. increased 
galectin-3 levels have been associated 
with various diseases, including can-
cer4,5, immunological disorders6,7, and 
cardiovascular traits.8,9 Plasma galec-
tin-3 levels are even being considered 
as a marker of response to cancer treat-
ment.10
 to enhance our knowledge on 
galectin-3 biology we performed the 
first genome-wide association study 
(Gwas) on circulating galectin-3 lev-
els and observed two loci associated 
with circulating galectin-3 levels. one 
locus harbours LGALS3 the gene en-
coding galectin-3 and the other locus 
harbours the ABO gene which has pre-
viously been associated with inflamma-
tory markers, lipids and haematological 
parameters.
r e s u l t s
we performed a Gwas analysis of 
2,269,099 genotyped or imputed au-
tosomal snPs (Hapmap 2 build 36 
ceu panel) in 3,776 subjects of the 
Prevend cohort (table 1, table s1). 
all included subjects were of european 
descent. The quantile-quantile plot for 
association is shown in figure 1. There 
were 2 loci significantly associated with 
galectin-3 levels (P < 5 × 10-8) and 11 
snPs showing suggestive evidence (P < 
5 × 10-6 and P > 5 × 10-8, figure 2, table 
2). we performed further testing of the 
lead-snP of the loci using an addition-
al subset of 3,516 independent subjects 
derived from the Prevend cohort 
(table 1). using inverse-variance fixed 
effect meta-analysis we combined the 
evidence. none of the suggestive, but 
both 2 P < 5 × 10-8 loci of the discovery 
phase, were confirmed in the independ-
ent samples (table 2). one locus har-
bours the LGALS3 gene and the other 
locus harbours the ABO gene (figure 
3). The LGALS3 locus accounted for 
25.6% of the phenotypic variance. The 
ABO locus explained 3.8% and togeth-
er LGALS3 and ABO explained 29.2% 
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Quantile-quantile plots of observed versus expected p-values 
for Galectin-3 with and without the Gals3 locus. 
figure 2. 
manhattan plot showing the association of snPs with cir-
culating galectin-3 levels in a Gwas of 3,776 individuals. 
The dotted line marks the threshold for genome-wide sig-
nificance (P = 5 × 10−8). two loci reached genome-wide sig-
nificance.
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of the phenotypic variance. of note, 
common genetic variation explained 
twice the amount of the variation of 
circulating galectin-3 levels compared 
to age, age squared (age2), gender, and 
body mass index combined (11.6%).
Putative causal genetic variants
The lead snP (rs2274273) of the 
LGALS3 locus lies in high ld with 
two non-synonymous variants (rs4644; 
r2=1.0 and rs4652; r2=0.91). as these 
variants were not present on our plat-
form and not well imputed we wet-lab 
genotyped these variants and con-
firmed their association (table 2). we 
next considered potential confounding 
by the specific galectin-3 assay used 
and noticed the epitopes of the anti-
bodies used are directed against the 
region harbouring the non-synony-
mous variant (figure 4). Therefore, this 
variant might affect the affinity of the 
antibody and not represent a true dif-
ference in circulating galectin-3 levels. 
we did not find variants in high ld 
(r2 > 0.8) associated with the lead snP 
(rs644234) of the ABO locus. next, 
we searched for eQtls in 1,469 sam-
ples from peripheral blood for which 
gene expression levels were obtained 
using illumine Ht12v3 and illumine 
H8v2 platforms11. rs2274273, rs4644, 
and rs4652 were all associated with 
LGALS3 gene expression levels (table 
3) and rs2274273 and rs4644 were also 
the strongest snP associated with that 
particular LGALS3 probe. finally, to 
gain further insights we queried the 
catalogue of published genome wide 
association studies12 for our loci and 
observed no previous associations for 
the LGALS3 locus but many previous 
genome wide associations findings have 
been reported for the ABO locus. Pre-
vious snP associations in or near ABO 
are in high linkage disequilibrium with 
our lead snP and include associations 
with inflammatory markers, lipids and 
haematological parameters as well as 
diseases such as cancer and coronary 
heart disease (table s2). 
relevance of the lgals3 variant for 
Prognostic value of Plasma galectin-3 
levels
to study the relevance of the rs2274273 
and rs4644 (r2=1) variant in the 
LGALS3 locus for the prognostic val-
ue of the galectin-3 assay on mortality 
in the general population we repeated 
our earlier reported analyses13 with and 
without rs2274273 as a covariate in the 
model. knowledge of the genotype did 
not appear to change the prognostic 
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fig.3b
figure 3. 
regional plots at the two significantly associated loci. Hori-
zontal axis indicates chromosomal location and P-values are 
indicated in the left y-axis. each plot shows approximately 
± 500 kb around each lead snP and has known gene tran-
scripts annotated at the bottom. The snPs are colored ac-
cording to their degree of linkage disequilibrium (r2) with 
the lead snP which is highlighted with a purple diamond 
and displayed by rs number and significance level achieved 
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d i s c u s s i o n
we report the first genetic association 
study on galectin-3 levels and identified 
2 genome-wide significant loci; one in-
cluding the galectin-3 encoding gene 
(LGALS3) and the other gene being 
ABO.
 Galectin-3 is a member of the 
galectin family that comprises of lec-
tins with affinity for beta-galactosidases 
containing carbohydrates. The galectin 
gene family is evolutionarily ancient 
and can be found in vertebrates, inver-
tebrates, and even in protists suggest-
ing an important role in biology.14 all 
galectins have a carbohydrate-recogni-
tion domain (crd) consisting of many 
conserved sequence elements and each 
galectin has an individual carbohy-
drate-binding preference.15 Galectin-3 
is an unique galectin as it contains a 
non-lectin n-terminal region which is 
connected to the crd. Galectin-3 is 
therefore referred to as a chimera-like 
galectin.1 Galectin-3 does not contain 
a signal sequence and is primarily lo-
calised within the cytoplasm. it can 
be externalized by a mechanism inde-
pendent of the endoplasmic reticulum 
(er)-Golgi complex.16,17 Galectin-3 has 
high affinity for lactose and n-acetyl-
lactosamine but can also interact with 
a wide array of other carbohydrates, 
membrane and extracellular matrix 
proteins.18 upon ligand binding, galec-
tin-3 (and its ligands) forms cross-links, 
is involved in strengthening cell-cell in-
teractions, and is associated with stiff-
ening of the extracellular matrix and fi-
brogenesis. Galectin-3 has been shown 
to play a role in inflammatory diseases, 
cancer and heart failure.3,15,19,20 little is 
known about the regulation of galec-
tin-3. The galectin-3 promoter contains 
several responsive elements, including 
sp-1, aP-1 and camP responsive ele-
ments.21
 we now report the first 2 ge-
nome wide associations with circulating 
galectin-3 levels. The strongest locus 
is within the LGALS3 gene. The lead 
snP (rs2274273) is in full ld with 
two non-synonymous snPs (rs4644 
and rs4652) which were confirmed by 
follow-up genotyping. Both rs2274273 
and rs4644 affected LGALS3 gene-ex-
pression providing a potential expla-
nation for the observed effect. in the 
current study we also tested whether 
knowledge of the lead variant in the 
LGALS3 gene might obscure the asso-
ciation of plasma galectin-3 levels with 
outcome but it did not alter our pre-
viously published associations further 
supporting a true effect of these variant 
on galectin-3.13 However, some note of 
caution is warranted. associations of 
coding snPs (e.g. rs4644 and rs4652) 
that structurally change the properties 
of its encoded protein can give rise to 
false positive associations when that 
protein is also the phenotype under 
investigation. The non-synonymous 
snPs identified in our study also lies 
within or near the epitopes of the an-
tibodies used for the galectin-3 assay 
(figure 4). These antibodies might have 
different affinities for the amino acid 
change and therefore this association 
could also be artifactual. interference 
of antibody based assays with epitopes 
directed against regions harbouring 
non-synonymous variants are not novel 
and have previously been reported for 
the NPPA-NPPB locus when anP lev-
els were measured.22 although gene-ex-
pression analyses and association with 
outcome are suggesting a true effect, 
additional work will be required to 
define the precise mechanisms of our 
reported association at the LGALS3 lo-
cus.
 our second genome wide 
locus is the ABO locus. The ABO lo-
cus is becoming an increasingly com-
plex and pleiotropic locus. variants in 
ABO, and in high ld with our lead 
snP (rs644234), have been associat-
ed by genome wide association studies 
with various blood measured traits and 
diseases. This includes several inflam-
matory markers, lipids, hematological 
parameters, cancer, inflammatory dis-
eases, and cardiovascular diseases (ta-
ble s2). interestingly, galectin-3 levels 
also are associated with many of these 
conditions. Galectin-3 can indeed bind 
to polysaccharides of the aBo epitopes 
and even more strongly to the a- or 
B-histo-blood group epitopes versus the 
o group.23 However, this does not ex-
plain how the ABO gene variant affects 
circulating galectin-3 levels.
 in summary, we performed a 
Gwas on plasma galectin-3 levels and 
identified two genome wide significant 
loci, one including the LGALS3 gene 
and the other the ABO gene. The ori-
gins of these associations should be fur-
ther validated by means of functional 
experiments.
m e t H o d s
study PoPulation 
we studied subjects included in the 
Prevend cohort. The Prevend 
cohort has been described in detail 
elsewhere 13,24,25. in brief, 8,592 subjects 
were enrolled in the Prevend cohort 
in 1997-1998. subjects were asked to 
refrain from eating and drinking prior 
to their visit (fasting) in the outpatient 
clinic (between 8:00 a.um and 1:00 
pm) and blood samples were drawn and 
stored at -80c. The Prevend study 
was approved by the local medical eth-
ical committee, and is conducted in 
accordance with the guidelines of the 
declaration of Helsinki. all subjects 
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figure 4. 
amino acid sequence (41 to 100) of Galectin-3. The two 
antibodies used in the Galectin-3 assay recognize epitopes 
within the n-terminus of the protein (white-colored amino 
acids). The capture antibody of the galectin-3 assay binds 
to amino acids number 45 to 62 and the tracer antibody 
binds to amino acids number 70 to 100. indicated are the 
non-synonymous snPs rs4644 and rs4652.
fig.4
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provided written informed consent.
galectin-3 measurements
for 7,968 subjects plasma was available 
to measure plasma galectin-3 levels.[13] 
The galectin-3 assay is an enzyme-linked 
immunosorbent assay (BG medicine, 
inc., waltham, usa). This assay quan-
titatively measures the concentration of 
human galectin-3 levels in edta plas-
ma. This assay has high sensitivity (low-
er limit of detection 1.13 ng/ml) and 
exhibits no cross reactivity with colla-
gens or other members of the galectin 
family26. commonly used medication 
like ace-inhibitors, beta blockers, 
spironolactone, furosemide, acetylsal-
icylic acid, warfarin, coumarines, and 
digoxin have no interference with the 
assay26. all samples were assayed in 
duplicate. two standard controls were 
included in all runs: a lower control 
(expected value: 13.0-23.1 ng/ml) and 
a higher control (expected value: 48.9-
81.5 ng/ml). The average lower control 
results were 16.65±1.13 (coefficient of 
variance: 6.8%), and the average higher 
control results were 68.17±3.20 (coeffi-
cient of variance: 4.7%).
genotyPing, quality control & imPu-
tation
Genotyping in 4,016 of the total num-
ber of participants in Prevend was 
carried out using illumina Humancy-
tosnP-12 arrays. snPs were called us-
ing illumina Genome studio software. 
forty-seven subjects were excluded 
from analyses because call rates were 
<0.95. another 65 subjects were exclud-
ed because they were closely related as 
judged based on identity-By-descent 
estimation using Plink v1.07. Popula-
tion structure was assessed using Pca 
based on 16,842 independent snPs. 
Based on this analysis, an additional 
2 samples were excluded that diverged 
from the mean with at least 3 standard 
deviations (z-score > 3) for the first 5 
Pcas. another 35 subjects were ex-
cluded based on sex inconsistencies. 
we excluded samples with a genetic 
similarity > 0.1. of 87 subjects no phe-
notype was available because of missing 
plasma samples for assessment of Galec-
tin-3. as a consequence 3,776 (1,927 
males, 1,849 females) were available for 
Gwas analysis. snPs were excluded 
with a minor allele frequency of <0.01, 
call rate <0.95, or deviation from Har-
dy weinberg equilibrium (P < 1 × 10-
5). Genome wide genotype imputation 
was performed using Beagle v. 3.3.1 27, 
232,571 genotyped snPs were imput-
ed up to 2,269,099 autosomal snPs 
with ncBi build 36 of Phase ii Hap-
map ceu data (release 22) as reference 
panel. replication genotyping was per-
formed by kBiosciences (kBiosciences, 
Herts, uk) utilizing the snPline sys-
tem in an additional 3,516 independent 
subjects of the Prevend study. 
gene-exPression analyses
we investigated whether each of the 
associated variants had an effect on 
gene expression levels by mapping 
cis-expression quantitative trait loci 
(cis-eQtl) in 1,469 samples from pe-
ripheral blood, for which gene expres-
sion level measurements were obtained 
using illumina Ht12v3 and illumina 
H8v2 platforms11. since the genotypes 
were imputed using the ceu popula-
tion of Hapmap 2 release 24 as refer-
ence, eQtl effects were tested using 
the imputation dosage values. effects 
for snPs (maf > 5%, Hwe > 0.001) 
were considered cis-eQtls when the 
distance between the snP and the 
midpoint position of the probe was 
smaller than 1 mB. as multiple test-
ing correction, we controlled the false 
discovery rate (fdr) at 0.05, by com-
paring observed p-values to the null 
distribution obtained from permuting 
the expression phenotype labels rela-
tive to genotype labels 100 times. we 
also determined the top eQtl snP for 
each given probe and tested whether 
the Gwas snP had an independent 
effect on the associated gene expression 
probe after removing the effect of the 
top eQtl snP.
statistical analysis
Galectin-3 was non-normally distrib-
uted and was log transformed before 
regression analyses. we calculated re-
siduals of galectin-3 levels after adjust-
ment for age, age2, and gender. Gwas 
analyses were performed on residuals 
using an additive genetic model in 
Plink (v.1.07).28 The most significant 
(P < 5 × 10-8) snPs (lead snP) at each 
locus was taken forward for further 
testing. The explained variance of the 
significant associations was analysed 
using the directly genotyped variants 
from the replication stage. fixed-ef-
fect meta-analysis was performed us-
ing the variance weighting method 
of the metal software package to 
calculate the overall p-value. The cox 
proportional-hazards model was used 
to calculate the hazard ratio and 95% 
confidence intervals (ci) of galectin-3. 
Based on our previous work, sequential 
models were fitted without and with 
the snP of interest.13 The first model 
including no covariates (unadjusted) 
and the second model adjusted for age 
and gender and the third model ad-
justed for: age, gender, previous myo-
cardial infarction, previous stroke, hy-
pertension, hypercholesterolemia and 
diabetes. The assumptions underlying 
the proportional hazards model were 
tested and found valid.  analyses were 
performed using stata version 11.0 
for windows software (statacorp lP, 
college station, tX, usa).
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